Immunovant Inc

Research Immunovant Inc (IMVT) on Bullrun: market cap USD 7.91B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMVT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 7.91B
• Financial periodFY2026
• Net income-USD 505.61M
• Free cash flow-USD 407.32M

Valuation Snapshot

latest market cap is USD 7.91B.

About Immunovant Inc

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc.

Frequently asked questions

What is Immunovant Inc's market cap?

Immunovant Inc's market capitalization is USD 7.91B.

What does Immunovant Inc do?

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.